Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 491kB
Preview	PDF (Supplementary Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 733kB

Item Type:	Letter
Title:	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study
Creators:	Rambaldi, A. ORCID: https://orcid.org/0000-0002-3739-7502, Iurlo, A. ORCID: https://orcid.org/0000-0002-4401-0812, Vannucchi, A.M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A. ORCID: https://orcid.org/0000-0002-3246-4470, Carli, G., De Muro, M., Luciani, S., McMullin, M.F. ORCID: https://orcid.org/0000-0002-0773-0204, Cambier, N., Marolleau, J.P., Mesa, R.A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica, P., Manzoni, S. and Di Tollo, S.
Keywords:	Carbamates, Janus Kinase 2, Maximum Tolerated Dose, Mutation, Polycythemia Vera, Quality of Life
Source:	Leukemia
ISSN:	0887-6924
Publisher:	Nature Publishing Group
Volume:	34
Number:	8
Page Range:	2234-2237
Date:	August 2020
Official Publication:	https://doi.org/10.1038/s41375-020-0735-y
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year